FIELD: medicine.
SUBSTANCE: the present innovation deals with the ways for decreasing the levels of HbA1c, glucose of triglycerides, general cholesterol in plasma, increasing the level of HDL-cholesterol and delayed onset of diabetic retinopathy in diabetic or pre-diabetic mammal with the help of compounds - derivatives of piperazine acetamide, particularly, ranolazine. The innovation provides normalization of the above-mentioned metabolic parameters at minimizing unfavorable side actions of therapy conducted.
EFFECT: higher efficiency of therapy.
19 cl, 6 dwg, 16 ex, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USING AS INHIBITORS OF ALIPHATIC ACIDS OXIDATION | 2002 |
|
RU2300533C2 |
| COMBINED THERAPY INCLUDING SGLT INHIBITORS AND DPP4 INHIBITORS | 2009 |
|
RU2481106C2 |
| METHOD OF DIABETES TREATMENT | 2007 |
|
RU2442585C2 |
| AZOLES AS INHIBITORS OF MALONYL-COA-DECARBOXYLASE USEFUL AS METABOLIC MODULATING AGENTS | 2002 |
|
RU2258706C2 |
| DERIVATIVES OF HETEROARYLALKYLPIPERAZINE AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2001 |
|
RU2243970C1 |
| COMBINATED INHIBITORS OF FBP-ASE AND ANTIDIABETIC AGENTS FOR DIABETES TREATMENT | 2001 |
|
RU2328308C2 |
| COMBINATIONS OF ACTIVATOR (ACTIVATORS) OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR), AND INHIBITOR (INHIBITORS) OF STEROL ABSORPTION AND TREATMENT OF VASCULAR DISEASES | 2008 |
|
RU2483724C2 |
| O-ARYLGLUCOSIDE INHIBITORS OF SGLT2 AND METHOD FOR THEIR USING | 2001 |
|
RU2269540C2 |
| NEW ANTHRANILAMIDOPYRIDINEUREAS AS VEGF RECEPTOR KINASE INHIBITORS | 2005 |
|
RU2415850C2 |
| OBESITY TREATMENT | 2019 |
|
RU2822679C2 |
